FibroBiologics (FBLG) Projected to Post Earnings on Tuesday

FibroBiologics (NASDAQ:FBLG) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect FibroBiologics to post earnings of ($0.10) per share for the quarter.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, analysts expect FibroBiologics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroBiologics Stock Performance

FibroBiologics stock opened at $0.83 on Monday. The firm has a market cap of $31.78 million, a price-to-earnings ratio of -2.44 and a beta of -0.25. FibroBiologics has a 1 year low of $0.76 and a 1 year high of $13.59. The firm’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.74.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on FBLG shares. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of FibroBiologics in a research report on Tuesday, April 1st. D. Boral Capital reiterated a “buy” rating and set a $16.00 price objective on shares of FibroBiologics in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, FibroBiologics currently has a consensus rating of “Buy” and a consensus price target of $13.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.